

**To:** (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minvws.nl>  
**Cc:** (10)(2e) <(10)(2e)@minbuza.nl>; Jurriëns <(10)(2e)@minbuza.nl>  
**From:** (10)(2e)  
**Sent:** Tue 5/19/2020 8:10:31 PM  
**Subject:** RE: Introducing FIND and our COVID-19 response  
**Received:** Tue 5/19/2020 8:10:35 PM

(10)(2e) ik laat dit even over aan (10)(2e) die bij onze de relaties met de PDPs beheert.

Wij hebben een bijdrage aan FIND gesuggereerd in het kader van de AIV claim, maar de discussies hierover verlopen zo weinig transparant dat ik werkelijk geen idee heb hoe kansrijk dat is.  
 Een gesprek kan natuurlijk altijd en Catharina is een heel plezierige persoon om mee te spreken. We moeten alleen oppassen geen valse verwachtingen te wekken.

(10)(2e)

---

**From:** (10)(2e) <(10)(2e)@minvws.nl>  
**Sent:** dinsdag 19 mei 2020 18:21  
**To:** (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minbuza.nl>  
**Subject:** FW: Introducing FIND and our COVID-19 response

Ha (10)(2e)

Met beide heb ik contact gehad over deze outreach van FIND (Foundation for Innovative New Diagnostics).

Zij willen graag een gesprek met (10)(2e) 1 (10)(2e) als (10)(2e)

Zullen we een gezamenlijke webex organiseren met Boehme cs. om te beluisteren wat hun actieplan is en hoe dat zich verhoudt met de 2 mid die zij willen organiseren.

(10)(2b)

Wat zouden jullie denken van een call volgende week dinsdagmiddag?

(10)(2e)

---

**Van:** Catharina Boehme <(10)(2e)@finddx.org>  
**Verzonden:** 12 May 2020 10:54  
**Aan:** (10)(2e) <(10)(2e)@minvws.nl>  
**CC:** (10)(2e) <(10)(2e)@finddx.org>; (10)(2e) <(10)(2e)@finddx.org>; (10)(2e) <(10)(2e)@hkstrategies.com>  
**Onderwerp:** Introducing FIND and our COVID-19 response

Dear (10)(2e)

Thank you for helping us with an introduction to the Task Force Testing. I am the CEO of FIND and I am glad to share a brief description of FIND (Foundation for Innovative New Diagnostics) and our role in the global response to COVID-19. FIND is an international non-profit with HQ in Geneva and country offices in India, Vietnam, Kenya and South Africa. The main objective of FIND is to ensure, for all LMICs, equitable access to high-quality essential diagnostic tests. We have focussed to date on major public health priorities including TB, malaria, anti-microbial resistance, Neglected Tropical Diseases as well as outbreaks, such as SARS-Cov-2, and have recently taken on activities for non-communicable diseases.

At the onset of the COVID-19 crisis, we set up a [diagnostic pipeline](#) tracker; we prioritized a first set of tests and are conducting ongoing independent evaluations – [results](#) are immediately made public of course. We also have an [open call](#) for test performance data. All of these (and many other) activities are aimed at supporting prioritization, testing strategy decisions in countries, and to help working out the supply chain bottlenecks. We are working with African Society for Laboratory Medicine (ASLM) and the London School MOOC tailored for [COVID testing in LMIC settings](#). We have also, working closely WHO and other global health organizations, been the co-lead of a consortium working on equitable allocation of diagnostic tests for LMICs. These are but a few

of the activities, but we'd be happy to give you a more detailed overview.

FIND has been recently designated as the lead for the diagnostics pillar of the Access to COVID-19 Tools (ACT) Accelerator, launched by WHO on 24 April 2020. We are now working diligently, together with the Global Fund as our co-lead, and have begun work to ensure expedited progress on innovation and equitable access needs.

We were pleased with the response we received during the pledging event hosted by the European Commission, but important gaps still remain. I am attaching the investment case developed by FIND to highlight the resources needed to address the urgent diagnostic needs for COVID-19 adequately. This investment case does not include funding support for procurement and we are working with the team at The Global Fund to identify the key asks now and over the coming two years. We know that we USD 2 billion right now to avoid much greater costs down the line.

Indeed, diagnostic testing is not only at the centre of the health response to the COVID-19 pandemic, it is central to mitigating the major global economic disaster. The COVID-19 exit route is front of mind for governments and businesses alike, and effective tests and testing strategies are the linchpin for getting people back to work across the globe. We are therefore seeking support from world leaders and governments to ensure we can bolster the diagnostics response rapidly bringing simple and affordable tests to everyone across the world.

I will be pleased to speak to the Task Force Testing to discuss areas of collaboration and will appreciate an opportunity for a call in the coming days. I am copying my assistant who can help with scheduling.

Best regards,  
Dr Catharina Boehme  
CEO, FIND

Catharina Boehme  
M +41 (10)(26)  
[www.finddx.org](http://www.finddx.org)

Please be advised that FIND has now moved all Geneva-based staff to home office, on account of the COVID-19 outbreak.

---

Help save paper! Do you really need to print this email?

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is toezonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. De Staat aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. The State accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.